Dergiler / Turkish Journal of Hematology / 2002 / Cilt: 19 - Sayı: 3

Variable expression and hypermethylation of p16 gene in patients with T-ALL and cell lines

Sayfa
391–397
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Furthermore our data show that the p16 gene inactivation by hypermethylation and deletion may play a role in the leukemogenesis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The multi tumor suppressor genes MTS1 (CDKN2, p16INK4A) and MTS2 (CDKN1, p15INK4B) located at 9p21-22 are inactivated in some human cancers via several mechanisms including deletion and hypermethylation.
📊
Temel Bulgular & Veri:In hematological malignancies, deletion of p16/p15 locus has been shown to be highly specific to lymphoid malignancies, and more particularly to T-cell acute lymphoblastic leukemia (T-ALL).
💡
Sonuç & Katkı:Furthermore our data show that the p16 gene inactivation by hypermethylation and deletion may play a role in the leukemogenesis.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Lösemi · lenfositik · akut

Özet

The multi tumor suppressor genes MTS1 (CDKN2, p16INK4A) and MTS2 (CDKN1, p15INK4B) located at 9p21-22 are inactivated in some human cancers via several mechanisms including deletion and hypermethylation. In hematological malignancies, deletion of p16/p15 locus has been shown to be highly specific to lymphoid malignancies, and more particularly to T-cell acute lymphoblastic leukemia (T-ALL). We have investigated the deletion, methylation and p16 protein expression status of MTS1 in T-cell childhood acute lymphoblastic leukemia (19 cases) and cell lines[11] . On Southern blot homozygous deletions or hemizygous deletion with rearangement were detected in 4/19 T-ALL. The expression of p16 protein was not observed on Western blot in 4/ 15 T-ALL with intact p16 gene. The p16 gene was methylated 3/15 in T-ALL. Only one of three expressed p16 protein. The other 11/15 T-ALL had p16 protein expression but different level. Loss of MTS1 was observed in 3/11 cell lines. Cell line with MTS1 gene had p16 protein expression in 6/8. After treatment with the demethylating agent (5-AzoCyt) RD cell line showed p16 expression. This has not been observed with the other cell lines. Thus hypermethylation of MTS1 is rare in childhood T-ALL. Although inactivation of MTS1 by deletion is common in T-ALL and cell lines. Furthermore our data show that the p16 gene inactivation by hypermethylation and deletion may play a role in the leukemogenesis.

🔖

Bu Makaleye Atıf Yap

ÖZKUL, Y., JURICKOVA, I., FINDLEY, H. W. (2002). Variable expression and hypermethylation of p16 gene in patients with T-ALL and cell lines. Turkish Journal of Hematology, Cilt: 19 - Sayı: 3, 391–397. https://ajindex.com/articles/412989

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. irama T, Koeffler HP. Role of the cyclin-dependentkinase inhibitors in the development of cancer. Blo-od 1995
  2. Delmer A, Tang R, Senamaud-Beaufort C, PaterliniP, Brechot C, Zittoun R. Alterations of cyclin-depen-tent kinase 4 inhibitor (p16INK4A/MTSI) gene sut-ructure and expression in acute lymphoblastic le-ukemias. Leukemia 1995
  3. Wang QM, Lones JB, Studzinski GP. Cyclin-depen-dent kinase inhibitor p27 as a mediator of the G1-Sphase block induced by 1,25-dihydroxyvitamin D3in HL60 cells. Cancer Res 1996
  4. Takeuchi S, Bartram CR, Seriu T, Miller CW, ToblerA, Janssen JW, Reiter A, Ludwig WD, Zimmer-mann M, Schwaller J, Lee E, Miyoshi I, Koeffler HF.Analysis of a family of cyclin-dependent kinase in-hibitors: p15/MTS2/INK4B, p16/MTSI/INK4A, andp18 genes in acute lymphoblastic leukemia ofchildhood. Blood 1995
  5. 60 5.gawa S, Hirano N, Sato N, Takahashi T, TanakaK, Kurokawa M, Tanaka T, Mitani K, Yazaki Y, HiraiH. Homozygous loss of the cyclin-dependent kina-se 4-inhibitor (p16) gene in human leukemias. Blo-od 1994
  6. Serrano M, Hannon GJ, Beach DA. New regulatorymotif in cellcycle control causing specific inhibitionof cyclin D/CDK4. Nature 1993
  7. Stone S, Jiang P, Dayananth P, Tavtinian SV, Katc-her H, Parry D, Peters G, Kamb A. Comlex structu-re and regulation of the p16 (MTSI) lacus. CancerRes 1995
  8. Wiest JS, Franklin WA, Otstot JT, Forbey K, Varel-la-Garcia M, Rao K, Drabkin H, Gemmill R, AhrentS, Sidransky D, Saccomanno G, Fountain JW, An-derson MW. Identification of a novel region of ho-mozygous deletion on chromosome 9p in squamo-us cell carcinoma of the lung: The location of a pu-tative tumor suppressor gene. Cancer Res1997
  9. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD,Rollins BJ, Sidransky D. A novel p16INK4A transc-ript. Cancer Res 1995
  10. Siebert R, Willers CP, Schamm A, Fossa A, DresenIMG, Uppenkamp M, Nowrousian MR, Seeber S,Opalka B. Homozygous loss of the MTSI/p16 andMTS2/p15 genes in lymphoma and lymphoblasticleukaemia cell lines. Br J Haematol1995
  11. Guran S, Tunca Y, Imirzalioglu N. Hereditary TP53codon 292 and somatic P16(INK4A) codon 94 mu-tations in a Li-Fraumeni syndrome family. Cancergenet. Cytogenet 1999
  12. Cowan JM, Halaban R, Francke U. Cytogeneticanalysis of melanocytes from premalignant neviand melanomas. J Nat Cancer Inst 1988
  13. Herman JG, Merlo A, Mao LI, et al. Inactivation othe CDK2/p16/MTS1 gene is f